- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
OneSource Specialty Pharma's board approved the financial results for the quarter ending December 31, 2025. Consolidated revenue stood at Rs. 290.34 Cr, with a net loss of Rs. 88.70 Cr. Additionally, the group's wholly-owned subsidiaries Stelis Pte. Ltd. and OneSource Specialty Pte. Ltd. amalgamated, effective January 1, 2026.